39 related articles for article (PubMed ID: 20507734)
21. [Immobilization of streptavidin-tagged bioactive hTNF-alpha on biotinylated mucosal surface of the bladder wall for treatment of superficial bladder cancer in mice].
Chen Z; Tan WL; Huang X; Liang ZK; Xu CX; Gao JM
Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):936-40. PubMed ID: 20501361
[TBL] [Abstract][Full Text] [Related]
22. [Intravesical anchoring of streptavidin-tagged interleukin-4 fusion protein for immunotherapy of mouse superficial bladder cancer].
Zhang Z; Xu XL; Ma L; Li JL; Hu ZM; Gao JM
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):331-5. PubMed ID: 22883451
[TBL] [Abstract][Full Text] [Related]
23. The therapeutic potential of SA-sCD40L in the orthotopic model of superficial bladder cancer.
Zhang Z; Xu X; Zhang X; Chen X; Chen Q; Dong L; Hu Z; Li J; Gao J
Acta Oncol; 2011 Oct; 50(7):1111-8. PubMed ID: 21247263
[TBL] [Abstract][Full Text] [Related]
24. A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF.
Hu Z; Tan W; Zhang L; Liang Z; Xu C; Su H; Lu J; Gao J
J Cell Mol Med; 2010 Jun; 14(6B):1836-44. PubMed ID: 19627402
[TBL] [Abstract][Full Text] [Related]
25. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
[TBL] [Abstract][Full Text] [Related]
26. The Roles of T cells in Bladder Pathologies.
Wu J; Abraham SN
Trends Immunol; 2021 Mar; 42(3):248-260. PubMed ID: 33536141
[TBL] [Abstract][Full Text] [Related]
27. A novel immunotherapy for superficial bladder cancer by the immobilization of streptavidin-tagged bioactive IL-2 on the biotinylated mucosal surface of the bladder wall.
Huang X; Yu HS; Chen Z; Li JL; Hu ZM; Gao JM
Chin J Cancer; 2010 Jun; 29(6):611-6. PubMed ID: 20507734
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis and management of superficial bladder cancer.
Amling CL
Curr Probl Cancer; 2001; 25(4):219-78. PubMed ID: 11514784
[TBL] [Abstract][Full Text] [Related]
29. [Results obtained by intravesical instillation of BCG in superficial bladder tumors].
Romics I; Dietmar B; Christoph R
Orv Hetil; 1990 Jan; 131(1):25-8. PubMed ID: 2405331
[TBL] [Abstract][Full Text] [Related]
30. Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Mukherjee N; Svatek RS; Mansour AM
Urol Oncol; 2018 Mar; 36(3):103-108. PubMed ID: 29429897
[TBL] [Abstract][Full Text] [Related]
31. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature.
Saint F; Salomon L; Quintela R; Cicco A; Hoznek A; Abbou CC; Chopin DK
Eur Urol; 2003 Apr; 43(4):351-60; discussion 360-1. PubMed ID: 12667715
[TBL] [Abstract][Full Text] [Related]
32. From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa.
Ingersoll MA; Albert ML
Mucosal Immunol; 2013 Nov; 6(6):1041-53. PubMed ID: 24064671
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
